US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Phargentis signs early partnership with Euro-wide generic pharma company for its third major generic product

(March 23, 2022) Phargentis has entered an early license agreement with a major European pharmaceutical company over the third major generic inhaled therapy that Phargentis is developing - an interchangeable version of Fostair® (beclomethasone / formoterol), a best-selling pMDI asthma and COPD treatment with a 2020 turnover of 529 MUSD in Europe. Phargentis CEO Andrea Tam: “This is fantastic news and as with all our early partnerships it will play a key role in mitigating risk, limiting financial exposure and ultimately ensuring efficient and early market entry.”Phargentis has entered into

Phargentis achieves positive results in pilot PK study of its new generic version of COPD treatment indacaterol/glycopyrronium plus DPI device

Phargentis announces another important milestone in achieving positive results in the clinical pilot study of ‘Glide’, its new generic version of COPD treatment indacaterol/glycopyrronium plus Dry Powder Inhaler. The clinical study demonstrated good comparability between ‘Glide’ and originator product Ultibro®Breezhaler®. Phargentis will now proceed to the next pivotal phase of development, on schedule. Global sales of Ultibro[®]Breezhaler[®][ ]exceed 500 MUSD a year.Phargentis has entered the clinical development phase for its second generic inhalation product – the COPD therapy containing

Phargentis begins clinical development of early-entry generic version of COPD treatment indacaterol/glycopyrronium and DPI device

(16 December, 2021) Phargentis has begun clinical development of its capsule based DPI (Dry Powder Inhaler) product containing indacaterol/glycopyrronium (85 mcg/43 mcg) designed to be an early-entry, fully interchangeable generic version of the global COPD treatment Ultibro®Breezhaler®. Sales of the treatment exceed 500 MUSD a year. The news follows the recent announcement of the company’s first European sales of its generic Tiotropium bromide Dry Powder Inhaler. CEO Andrea Tam: “We are delighted to enter the clinical phase of development in this vital, highly effective product.”Phargentis

First European sales of generic Tiotropium bromide 18 µg DPI, developed by Phargentis

(November 10, 2021) Tiotropium bromide 18 µg Dry Powder Inhaler developed by Phargentis has been launched in Europe. It is the first generic product approved in the EU with precisely the same strength and same delivered dose as Spiriva®Handihaler®, the global first-line treatment for COPD. This generic equivalent has been delivered to the UK, Norway, Spain and the Netherlands, with formal pricing and substitution agreements agreed within those markets. Global turnover for Spiriva®Handihaler® in 2020 exceeded 2.5 bUSD (IQVIA).In May 2021 the generic Tiotropium bromide 18µg DPI, developed by

Generic Tiotropium bromide 18 µg DPI, developed by Phargentis, receives approval in 28 European countries

(November 11, 2021) Tiotropium bromide 18 µg Dry Powder Inhaler is the first generic product approved in the EU with the same strength and same delivered dose as Spiriva®Handihaler®, the global first line treatment for COPD – enabling possibility for full reimbursement across the European Union and other key international markets. Developed by Phargentis, it has now been approved in 28 European Countries. Global turnover for Spiriva®Handihaler® in 2020 exceeded 2.5 bUSD (IQVIA).Phargentis, an agile, small-scale pharmaceutical company headquartered in Switzerland, has earned the approval of

There are no items matching the current filter
There are no more items matching the current filter
Back to top